Valneva (NASDAQ:VALN) Shares Gap Up – What’s Next?

Valneva SE (NASDAQ:VALN)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $5.61, but opened at $6.21. Valneva shares last traded at $6.27, with a volume of 10,865 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Valneva in a research report on Friday, January 31st.

Valneva Stock Performance

The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The firm has a 50 day moving average price of $4.41 and a 200-day moving average price of $5.65. The stock has a market capitalization of $526.16 million, a PE ratio of -49.81 and a beta of 1.98.

Hedge Funds Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC increased its stake in shares of Valneva SE (NASDAQ:VALN) by 33.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 118,000 shares of the company’s stock after buying an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned about 0.15% of Valneva worth $717,000 at the end of the most recent quarter. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.